| Literature DB >> 31284642 |
Sandra Sordon1, Jarosław Popłoński2, Magdalena Milczarek3, Martyna Stachowicz3, Tomasz Tronina2, Alicja Z Kucharska4, Joanna Wietrzyk3, Ewa Huszcza2.
Abstract
Common food flavonoids: chrysin, apigenin, luteolin, diosmetin, pinocembrin, naringenin, eriodictyol, hesperetin, and their analogues with an additional hydroxyl group at the C-8 position obtained via biotransformation were tested for antioxidant activity using the ABTS, DPPH, and ferric ion reducing antioxidant power (FRAP) methods. They were also tested for antiproliferative activity against selected human cancer cell lines-MV-4-11 (biphenotypic B myelomonocytic leukemia), MCF7 (breast carcinoma), LoVo (colon cancer), LoVo/DX (colon cancer doxorubicin resistant), and DU 145 (prostate cancer)-and two normal human cell lines-MCF 10A (breast cells) and HLMEC (lung microvascular endothelial cells). Flavonoids with a C7-C8 catechol moiety indicated much higher antioxidant activity compared with the C7 hydroxy analogues. However, because they were unstable under the assay conditions, they did not show antiproliferative activity or it was very low.Entities:
Keywords: anticancer activity; antioxidant activity; catechol moiety; flavanones; flavones; hydroxylation
Year: 2019 PMID: 31284642 PMCID: PMC6680932 DOI: 10.3390/antiox8070210
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Chemical structures of tested flavonoids.
Inhibitory concentration 50 (IC50) values representing the antiproliferative activity of tested flavonoids against human cancer and normal cell lines.
| Compound | IC50 ± SD (µM) | ||||||
|---|---|---|---|---|---|---|---|
| MV-4-11 | MCF7 | LoVo | LoVo/DX | DU 145 | MCF 10A | HLMEC | |
|
| 15.14 ± 1.99 | 74.97 ± 26.08 | 28.01 ± 8.17 | 12.98 ± 1.29 | ND | 26.98 ± 11.96 | 22.85 ± 2.02 |
|
| 8.18 ± 2.76 | 22.50 ± 1.29 | 13.80 ± 1.38 | 11.58 ± 1.35 | 28.86 ± 8.4 | 35.67 ± 11.93 | 14.06 ± 0.91 |
|
| 8.73 ± 2.23 | 25.50 ± 6.33 | 13.45 ± 0.65 | 13.69 ± 1.65 | 21.94 ± 6.11 | 33.12 ± 10.31 | 9.22 ± 0.64 |
|
| 8.39 ± 3.53 | 122.73 ± 37.36 | 14.99 ± 2.2 | 13.39 ± 3.02 | ND | ND | 14.39 ± 1.95 |
|
| 99.12 ± 34.11 | 147.63 ± 6.57 | 116.10 ± 10.63 | 67.04 ± 15.81 | 118.60 ± 22.45 | 125.19 ± 5.77 | 96.59 ± 7.23 |
|
| 146.19 ± 19.09 | 215.35 ± 32.28 | 120.84 ± 4.3 | 128.67 ± 9.74 | 241.65 ± 15.61 | 185.16 ± 23.19 | 113.98 ± 18.55 |
|
| ND | 150.70 ± 9.31 | 100.68 ± 10.86 | 99.22 ± 12.46 | 120.66 ± 18.45 | 146.61 ± 36.21 | 25.81 ± 6.71 |
|
| 140.47 ± 12.93 | 167.33 ± 13.12 | 103.81 ± 5.55 | 77.25 ± 19.39 | 214.54 ± 32.09 | 206.97 ± 23.42 | 98.29 ± 7.62 |
|
| ND | ND | ND | ND | ND | ND | 119.60 ± 2.24 |
|
| ND | ND | 235.29 ± 57.07 | ND | ND | ND | 122.21 ± 14.38 |
|
| ND | ND | 237.76 ± 35.36 | ND | ND | ND | 105.98 ± 1.72 |
|
| ND | ND | 223.65 ± 15.29 | ND | ND | ND | 107.70 ± 15.4 |
|
| ND | ND | ND | ND | ND | ND | 148.50 ± 13.38 |
|
| ND | 121.80 ± 4.11 | ND | ND | ND | ND | 110.22 ± 0.18 |
|
| ND | 115.53 ± 7.1 | 179.49 ± 31.97 | ND | ND | 202.93 ± 93.02 | 90.68 ± 18.85 |
|
| ND | 135.45 ± 20.25 | ND | ND | ND | ND | 97.06 ± 5.15 |
|
| 1.60 ± 0.33 | 7.50 ± 1.32 | 5.87 ± 1.72 | 3.23 ± 0.77 | 1.47 ± 0.12 | 10.63 ± 1.17 | 1.07 ± 0.05 |
SD—standard deviation; ND—not determined in the range of tested concentrations (100; 10; 1; 0.1 µg/mL); * ratio 19:1 (by HPLC); ** ratio 1:1.3 (by HPLC).
Figure 2Antioxidant activity of tested compounds (1–18) determined in separate tests: ABTS, DPPH, and ferric ion reducing antioxidant power (FRAP).